tbuckley/cabot-search huggingface dataset:
Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy
Authors: Sarah L. DeVos, Rebecca L. Miller, Kathleen M. Schoch, Brandon B. Holmes, Carey S. Kebodeaux, Amy J. Wegener, Guo Chen, Tao Shen, Hien Tran, Brandon Nichols, Tom A. Zanardi, Holly B. Kordasiewicz, Eric E. Swayze, C. Frank Bennett, Marc I. Diamond, Timothy M. Miller
Journal: Science Translational Medicine (2017)

Antisense oligonucleotides that reduce tau prevent neuronal loss and reverse tau deposition and seeding in a mouse model of tauopathy.
A Plea to Expand the Scope of Tumor Boards
Authors: Tonia M. Young-Fadok
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Chronic urticaria and atopic disorders: a cross-sectional study of 11 271 patients
Authors: G. Shalom, E. Magen, J. Dreiher, T. Freud, B. Bogen, D. Comaneshter, D.A. Vardy, R. Khoury, N. Agmon-Levin, A.D. Cohen
Journal: British Journal of Dermatology (2017)

Chronic urticaria (CU) and atopic disorders such as atopic dermatitis (AD), allergic rhinoconjunctivitis (AR), and asthma are related to aberrant immune function. The relationship between atopic disorders and CU is controversial, mostly since epidemiological data are lacking.

The aim of our study was to investigate the association between CU and asthma, AD, and AR using a database of Clalit Health Services (CHS) - the largest healthcare provider organization in Israel.

This article is protected by copyright. All rights reserved.
Successful endoscopic closure using over-the-scope clip for delayed stomach perforation caused by nasogastric tube after endoscopic submucosal dissection
Authors: Seiichiro Abe, Takeyoshi Minagawa, Hirohito Tanaka, Ichiro Oda, Yutaka Saito
Journal: Endoscopy (2017)

A 55-year-old woman was found to have a depressed lesion on the posterior part of the lower gastric body ([Fig. 1 a]). The patient underwent endoscopic submucosal dissection (ESD) and en bloc resection without intraoperative perforation. Prophylactic endoscopic coagulation using Coagrasper (Olympus Medical, Tokyo, Japan) was performed for visible vessels, and endoclips were applied prophylactically to close tiny injuries to the muscularis propria ([Fig. 1 b]). As significant bile juice reflux was noticed during endoscopy, a 14-Fr soft nasogastric tube was inserted. Smooth drainage of gastric fluid was observed.
MiR-194 functions as a tumor suppressor in laryngeal squamous cell carcinoma by targeting Wee1
Authors: Pei Li, Yang Yang, Hui Liu, An-Kui Yang, Jin-Ming Di, Guang-Mou Tan, Hai-Feng Wang, Jian-Ge Qiu, Wen-Ji Zhang, Qi-Wei Jiang, Di-Wei Zheng, Yao Chen, Meng-Ning Wei, Jia-Rong Huang, Kun Wang, Zhi Shi, Jin Ye
Journal: Journal of Hematology & Oncology (2017)

The emerging roles of microRNAs (miRs) have been deeply investigated in cancer. However, the role of miR-194 in human laryngeal squamous cell carcinoma (LSCC) is still unclear. Here, we have demonstrated that miR-194 is significantly downregulated in LSCC tissues and cells, and overexpression of miR-194 inhibits the proliferation, migration, invasion, and drug resistance in LSCC cells. Moreover, Wee1 is identified as a novel direct target of miR-194. Ectopic expression of Wee1 at least in part overcomes the suppressive impacts of miR-194 on the malignant phenotypes of LSCC. Overall, our study provides new sights into the role of miR-194/Wee1 axis in LSCC and suggests a novel miR-194/Wee1-based clinical application for LSCC patients.
Nilotinib Treatment Post - Allogeneic Stem Cell Transplantation (alloSCT) in Advanced (&gt;CP1) Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL).
Authors: Arnon Nagler, Yulia Volchek, Ronit Yerushalmi, Nira Varda-Bloom, Raz Somech, Tali Tohami, Ninette Amariglio, Avichai Shimoni
Journal: Blood (2009)
Electrophysiological effects of nicardipine hydrochloride on the isolated sinoatrial and atrioventricular nodes of the rabbit.
Authors: Toshitake Tamamura, Tomotsugu Konishi, Hiroko Matsuda, Makoto Kadoya, Shoichi Yokoyama, Chuichi Kawai
Journal: Circulation (1983)

The electrophysiological effects of nicardipine-HCl, a new calcium antagonist and potent vasodilator, were studied in the isolated sinoatrial (SA) and atrio-ventricular (AV) nodes of the rabbit in an oxygenated Tyrode solution at 35 degrees C using an intracellular microelectrode technique. Nicardipine-HCl decreased the spontaneous rate of the SA node and prolonged sinus recovery time, dose-dependently. The effective refractory period (ERP) and functional refractory period (FRP) of the AV node and AV conduction time (A-H interval) were also prolonged by nicardipine-HCl in a dose-dependent manner. In conclusion, nicardipine-HCl has electrophysiological effects on the SA and the AV node similar to those of other calcium antagonists in the excised and superfused rabbit heart.
Epidemiological and Clinico-Pathological Features of Systemic Peripheral T-Cell Lymphomas (PTCL): A Population-Based Analysis from the Danish Lymphoma Registry LYFO
Authors: Francesco d’Amore, Peter de Nully Brown, Lars Moeller Pedersen, Anne Bukh, Per Boye Hansen, Bjarne Bach Pedersen, Ole Gadeberg, Michael Pedersen, Steen Ingeberg, Stanislaw Pulczynski, Torben Mourits Andersen, Michael Moeller
Journal: Blood (2008)
Outcomes of Unrelated Umbilical Cord Blood Transplantation Using a Conditioning Regimen of TBI/Ara-c/CY without ATG for Adolescent and Adults Patients with High-Risk Hematologic Malignancies
Authors: Zimin Sun, Huilan Liu, Liangquan Geng, Xingbing Wang, Kaiyang Ding, Juan Tong, Baolin Tang, Chenyang Zhou, Wen Yao, Yun Wu, Changcheng Zheng, Xin Liu, Weibo Zhu, Zhuyi Wang
Journal: Blood (2012)
CYP27A1 Loss Dysregulates Cholesterol Homeostasis in Prostate Cancer
Authors: Mahmoud A. Alfaqih, Erik R. Nelson, Wen Liu, Rachid Safi, Jeffery S. Jasper, Everardo Macias, Joseph Geradts, J. Will Thompson, Laura G. Dubois, Michael R. Freeman, Ching-yi Chang, Jen-Tsan Chi, Donald P. McDonnell, Stephen J. Freedland
Journal: Cancer Research (2017)

Abstract In this study, we used a bioinformatic approach to identify genes whose expression is dysregulated in human prostate cancers. One of the most dramatically downregulated genes identified encodes CYP27A1, an enzyme involved in regulating cellular cholesterol homeostasis. Importantly, lower CYP27A1 transcript levels were associated with shorter disease-free survival and higher tumor grade. Loss of CYP27A1 in prostate cancer was confirmed at the protein level by immunostaining for CYP27A1 in annotated tissue microarrays. Restoration of CYP27A1 expression in cells where its gene was silenced attenuated their growth in vitro and in tumor xenografts. Studies performed in vitro revealed that treatment of prostate cancer cells with 27-hydroxycholesterol (27HC), an enzymatic product of CYP27A1, reduced cellular cholesterol content in prostate cancer cell lines by inhibiting the activation of sterol regulatory-element binding protein 2 and downregulating low-density lipoprotein receptor expression. Our findings suggest that CYP27A1 is a critical cellular cholesterol sensor in prostate cells and that dysregulation of the CYP27A1/27HC axis contributes significantly to prostate cancer pathogenesis. Cancer Res; 77(7); 1662–73. ©2017 AACR.
Antimitoic Peptides: Synergistic Anticancer Effect of Peptide‐Docetaxel Nanoassembly Targeted to Tubulin: Toward Development of Dual Warhead Containing Nanomedicine (Adv. Healthcare Mater. 2/2017)
Authors: Saswat Mohapatra, Abhijit Saha, Prasenjit Mondal, Batakrishna Jana, Subhajit Ghosh, Atanu Biswas, Surajit Ghosh
Journal: Advanced Healthcare Materials (2017)

In article 1600718, Surajit Ghosh and co-workers describe the development of a highly bioavailable novel breast cancer cell specific liposomal nano-vesicle, which contains combination of microtubule targeted therapeutics such as docetaxel and tubulin targeted peptide. It causes severe intracellular microtubule depolymerization, significant synergistic apoptotic death, inhibition of migration of triple negative metastatic cancer cell and reduction of tumor mimicking 3D spheroid growth.
Phase I-II Study of Dose Dense PEG-Filgrastim and GM-CSF as Support for Dose Dense CHOP-R Front Line Therapy for Aggressive Non-Hodgkin's Lymphoma (NHL).
Authors: Maribel Cotto, Fernando Cabanillas, Idalia Liboy, Ezequiel Rivera, Orestes A. Pavia, Margarita Bruno
Journal: Blood (2010)
The Effects of Romiplostim or Standard of Care (SOC) on Splenectomy and Treatment Failure of Patients Who Had Immune Thrombocytopenia (ITP) for Less Than or Equal to One Year.
Authors: Ralph Boccia, David J. Kuter, Mathias J. Rummel, B. Gail Macik, Ingrid Pabinger, Dominik Selleslag, Francesco Rodeghiero, Beng Chong, Xuena Wang, Richard Lizambri
Journal: Blood (2010)
Superior Complete Remission/Very Good Partial Remission Rate with Peri-Transplant Administration of Thalidomide-Dexamethasone for Newly Diagnosed Multiple Myeloma.
Authors: Michele Cavo, Elena Zamagni, Patrizia Tosi, Delia Cangini, Paola Tacchetti, Claudia Cellini, Nicoletta Testoni, Chiara Nicci, Antonio de Vivo, Giulia Perrone, Michela Ceccolini, Michele Baccarani
Journal: Blood (2005)
Fentanyl Sublingual Tablets Versus Subcutaneous Morphine for the Management of Severe Cancer Pain Episodes in Patients Receiving Opioid Treatment: A Double-Blind, Randomized, Noninferiority Trial
Authors: Ernesto Zecca, Cinzia Brunelli, Fabio Centurioni, Andrea Manzoni, Alessandra Pigni, Augusto Caraceni
Journal: Journal of Clinical Oncology (2017)

Purpose Fentanyl sublingual tablets (FST) are a potentially useful alternative to parenteral opioids such as subcutaneous morphine (SCM) to treat severe cancer pain episodes. No direct comparison between FST and SCM is available. The aim of this study was to test noninferiority of FST versus SCM during the first 30 min postadministration. Methods Patients receiving stable opioid therapy and experiencing a severe pain episode were randomly assigned to either 100 µg FST or 5 mg SCM in a double-blind, double-dummy trial. Average pain intensity (PI) assessed on a 0 to 10 numerical rating scale at 10, 20, and 30 min postadministration was the main end point. Analysis of covariance, adjusted by baseline PI, was the main analysis. The noninferiority margin (NIm) for the between-group difference was set at -0.6, that is, equal to one third of the minimum clinically important PI difference of two points. Results A total of 114 patients were randomly assigned to either FST (n = 58) or SCM (n = 56). One patient (in the FST group) withdrew consent before drug administration and was excluded from analysis. Baseline mean PIs were 7.5 in both groups; mean average PIs assessed at 10, 20, and 30 min postadministration were 5.0 and 4.5 for FST and SCM, respectively, with the 95% CI of the between-group difference including the NIm (-0.49; 95% CI, -1.10 to 0.09). Patients taking FST received a second drug dose after 30 min more frequently than did patients taking SCM (51% v 37%, respectively; risk difference, -13%; 95% CI, -30% to 3%). Both treatments were well tolerated, with average follow-up adverse event scores below the response of "A Little." Ninety-three percent of patients preferred the sublingual administration. Conclusion This trial did not show noninferiority of FST versus SCM within the chosen NIm. Both treatments were safe, and patients preferred the sublingual route of administration. FST provides analgesia with modest to moderate increased risk of lower efficacy compared with SCM.
P-Glycoprotein Modulation Facilitates the Selective Inhibition of Oxidative Phosphorylation in Alloreactive T Cells to Prevent Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplant
Authors: Zachariah A. McIver, James P Phipps, Jason M Grayson, Jacqueline E Hill, Gregory A Schamerhorn, Tymish Y Ohulchanskyy, Michelle K Linder, Kellie S Davies, Roy S Weiner, Michael R Detty
Journal: Blood (2015)
Myelodysplastic Syndrome (MDS)-Specific Comorbidity Index for Predicting the Impact of Extra-Hematological Comorbidities on Survival of Patients with MDS
Authors: Matteo G Della Porta, Andrea Kuendgen, Luca Malcovati, Esther Zipperer, Cristiana Pascutto, Erica Travaglino, Margherita Maffioli, Ilaria Ambaglio, Rosangela Invernizzi, Ulrich Germing, Mario Cazzola
Journal: Blood (2008)
Gastrointestinal Stromal Tumors in Younger Patients
Authors: Donal B. O’Connor, Kevin C. Conlon
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Atenolol treatment for infantile haemangioma
Authors: M. Tasani, M. Glover, A.E. Martinez, L. Shaw
Journal: British Journal of Dermatology (2017)

Since 2008, propranolol has become the first line recommended treatment for infantile haemangiomas (IH) 1,2. Propranolol is a synthetic beta-adrenergic receptor-blocking agent that is non-selective because it blocks both beta 1 and beta 2 adrenergic receptors 3,4. The most commonly reported side effects in infants treated with propranolol for IH are sleep disturbance, cool mottled peripheries and bronchial hyperactivity 3,5 and concerns have been raised about the potential long-term neurodevelopmental or cognitive effects6, 7. A proportion of patients has to stop treatment because of adverse effects, thus treatments with other beta-blockers are considered.

This article is protected by copyright. All rights reserved.
Optimizing Mobilization, Augmentation, and Gene Transfer of Multipotent Mesenchymal Stromal Cells (MSCs).
Authors: Stephen R. Larsen, Keefe Chng, Shangzhen Zhou, John Wright, Margaret Armstrong, Sally Thompson, Annemarie Hennessy, Rosetta Martiniello-Wilks, John Gibson, Douglas E. Joshua, John E.J. Rasko
Journal: Blood (2006)
Drainage endoscopique trans-fistuleux pour collections abdominales après chirurgie bariatrique communiquant avec le tractus digestif haut
Authors: G. Lesur
Journal: Endoscopy (2016)

Le traitement des collections intra-abdominales après chirurgie bariatrique est toujours délicat. Le traitement de référence consiste en un drainage percutané associé à la mise en place d‘une prothèse métallique longue. Cependant, ce traitement est parfois en échec.
Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease
Authors: Tim E. Moors, Jeroen J. M. Hoozemans, Angela Ingrassia, Tommaso Beccari, Lucilla Parnetti, Marie-Christine Chartier-Harlin, Wilma D. J. van de Berg
Journal: Molecular Neurodegeneration (2017)

Converging evidence from genetic, pathological and experimental studies have increasingly suggested an important role for autophagy impairment in Parkinson's Disease (PD). Genetic studies have identified mutations in genes encoding for components of the autophagy-lysosomal pathway (ALP), including glucosidase beta acid 1 (GBA1), that are associated with increased risk for developing PD. Observations in PD brain tissue suggest an aberrant regulation of autophagy associated with the aggregation of α-synuclein (α-syn). As autophagy is one of the main systems involved in the proteolytic degradation of α-syn, pharmacological enhancement of autophagy may be an attractive strategy to combat α-syn aggregation in PD. Here, we review the potential of autophagy enhancement as disease-modifying therapy in PD based on preclinical evidence. In particular, we provide an overview of the molecular regulation of autophagy and targets for pharmacological modulation within the ALP. In experimental models, beneficial effects on multiple pathological processes involved in PD, including α-syn aggregation, cell death, oxidative stress and mitochondrial dysfunction, have been demonstrated using the autophagy enhancers rapamycin and lithium. However, selectivity of these agents is limited, while upstream ALP signaling proteins are involved in many other pathways than autophagy. Broad stimulation of autophagy may therefore cause a wide spectrum of dose-dependent side-effects, suggesting that its clinical applicability is limited. However, recently developed agents selectively targeting core ALP components, including Transcription Factor EB (TFEB), lysosomes, GCase as well as chaperone-mediated autophagy regulators, exert more specific effects on molecular pathogenetic processes causing PD. To conclude, the targeted manipulation of downstream ALP components, rather than broad autophagy stimulation, may be an attractive strategy for the development of novel pharmacological therapies in PD. Further characterization of dysfunctional autophagy in different stages and molecular subtypes of PD in combination with the clinical translation of downstream autophagy regulation offers exciting new avenues for future drug development.
Multicenter Validation of Spin-Density Projection-Assisted R2-MRI for the Non-Invasive Measurement of Liver Iron Concentration
Authors: Timothy G St Pierre, Amal El-Beshlawy, Mohsen Saleh Elalfy, Abdullah Al Jefri, Kusai Al Zir, Shahina Daar, Dany Habr, Ulrike Kriemler-Krahn, Ali Taher
Journal: Blood (2010)
The Opposing Role of Histone Deacetylase 10 (HDAC10) and HDAC11 in Proliferation/Survival of Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL)
Authors: Eva Sahakian, Bijal D. Shah, John Powers, Susan Deng, Oscar Merino, Ajaypal S. Gill, Jennifer Rock-Klotz, Karrune V. Woan, Lianet Vazquez, Hongwei Wang, Selina Chen-Kiang, Jianguo Tao, Alejandro Villagra, Javier Pinilla-Ibarz, Eduardo M. Sotomayor
Journal: Blood (2011)
Inhibition of TLX3 and NKX2-5 in t(5;14)(q35;q32) T-ALL after Blocking Remote 3′-BCL11B Enhancer Sequences with Matching DNA Oligos Reveals Coregulation by PU.1 and HMGA1.
Authors: Stefan Nagel, Michaela Scherr, Alexander Kel, Klaus Hornischer, Gregory E. Crawford, Maren Kaufmann, Corinna Meyer, Hans G. Drexler, Roderick A.F. MacLeod
Journal: Blood (2006)
First-Line Treatment of Multiple Myeloma with a Combination of Thalidomide, Dexamethasone, and Zoledronate (TDZ) in an Inner-City Population with High HIV Prevalence.
Authors: Uwe Klueppelberg, Eric Smith, Laurie Chen, Chona M. Aloba, Iuliana Shapira, Mehdi M. Moezi, Olcay Batuman
Journal: Blood (2004)
Inhibition of Reticulon-1A–Mediated Endoplasmic Reticulum Stress in Early AKI Attenuates Renal Fibrosis Development
Authors: Ying Fan, Wenzhen Xiao, Kyung Lee, Fadi Salem, Jiejun Wen, Li He, Jing Zhang, Yang Fei, Dongsheng Cheng, Hongda Bao, Yumei Liu, Fujun Lin, Gengru Jiang, Zhiyong Guo, Niansong Wang, John Cijiang He
Journal: Journal of the American Society of Nephrology (2017)

Several animal studies have shown an important role for endoplasmic reticulum (ER) stress in AKI, whereas human studies are lacking. We recently reported that Reticulon-1A (RTN1A) is a key mediator of ER stress and kidney cell injury. Here, we investigated whether modulation of RTN1A expression during AKI contributes to the progression to CKD. In a retrospective study of 51 patients with AKI, increased expression of RTN1A and other ER stress markers were associated with the severity of kidney injury and with progression to CKD. In an inducible tubular cell–specific RTN1A-knockdown mouse model subjected to folic acid nephropathy (FAN) or aristolochic acid nephropathy, reduction of RTN1A expression during the initial stage of AKI attenuated ER stress and kidney cell injury in early stages and renal fibrosis development in later stages. Treatment of wild-type mice with tauroursodeoxycholic acid, an inhibitor of ER stress, after the induction of kidney injury with FA facilitated renoprotection similar to that observed in RTN1A-knockdown mice. Conversely, in transgenic mice with inducible tubular cell–specific overexpression of RTN1A subjected to FAN, induction of RTN1A overexpression aggravated ER stress and renal injury at the early stage and renal fibrosis at the late stage of FAN. Together, our human and mouse data suggest that the RTN1A-mediated ER stress response may be an important determinant in the severity of AKI and maladaptive repair that may promote progression to CKD.
High Frequency of C-Terminal Frame-Shift Mutations of RUNX1 Gene in De Novo AML with Partial Tandem Duplication of MLL.
Authors: Chein-Fuang Huang, Lee-Yung Shih, Der-Cherng Liang, Sung-Tzu Liang, Jen-Fen Fu, Yu-Shu Shih, Chia-Ling Chang, Jo-Chuan Liu, Wen-Hsin Hsu, Chang-Liang Lai
Journal: Blood (2009)
High WT1 Expression Is Associated with a Shorter Time to Complete Remission After ATRA Based Induction Therapy In Acute Promyelocytic Leukemia
Authors: Florian Nolte, Daniel Nowak, Anna Hecht, Philipp Erben, Benjamin Hanfstein, Ouidad Benlasfer, Thomas Buchner, Wolf-Karsten Hofmann, Eva Lengfelder
Journal: Blood (2010)